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Abstract: This study proposes a new approach to the responsible development of innovative products, processes and
services by companies and organisations operating in the bioeconomy and related industry sectors. It departs from
much of the recent and currently available research on responsible research and innovation in that it recognises the
very different challenges faced by innovating organisations, compared to conventional approaches with a strong
emphasis on upstream engagement. It attempts to move away from the politicised perspectives that have dominated
many engagement initiatives on disruptive innovations like synthetic/engineering biology, and to focus on practical
downstream outcomes, the extent to which they will fulfil the aspirations of ordinary citizens, and will comply with
prevailing industry norms of responsible behaviour. The proposed consolidated responsible innovation framework
builds on the framework developed in 2012 by the then Technology Strategy Board, implemented using the anticipate,
reflect, engage and act approach devised by UK research councils. It distinguishes between routine, company-specific
aspects of responsibility, expected to be addressed within an organisation’s standard operating procedures, and
project-specific aspects requiring regular appraisal throughout the development of an innovation. It is designed to be
simple and feasible for a company to implement within a commercial environment.1 The concept of responsible research
and innovation (RRI)
A common expectation in most societies is that innovation will
continue to improve our lives through economic, health-related or
environmental benefits [1, 2] and the Organisation for Economic
Cooperation and Development sees much of that innovation
coming from the bioeconomy – ‘From a broad economic
perspective, the bioeconomy refers to the set of economic
activities relating to the invention, development, production and
use of biological products and processes. If it continues on course,
the bioeconomy could make major socioeconomic contributions
… to improve health outcomes, boost the productivity of
agriculture and industrial processes, and enhance environmental
sustainability.’ [3]. The current scale of the UK bioeconomy was
estimated in 2015 to be least £150 billion gross value added
(GVA), supporting ∼600 K jobs, and potentially increasing GVA
by a further £40 billion over the coming decade [4], and synthetic
biology is expected to transform the sustainability and productivity
of the industries that contribute to the bioeconomy [5].
There are some potential barriers to the delivery of these expected
benefits. There is considerable variation, nationally and societally,
in the ways we perceive the risks and benefits of innovative
technologies, and the governance processes we put in place for
an innovative technology area will determine not just which
products and processes are developed but also what scale of
company can participate in their development and ultimately the
competitive advantage of nations and regions [6]. With this in
mind, RRI is being promoted as an essential component of
future European Union (EU) governance processes, with a focus
on synthetic biology as a leading example, through an extensive
and long-running programme of academic research funding
initiatives, the assumption being that RRI will be a key component
of future EU governance processes and hence to delivering
societal acceptance of these technologies.
The European Commissioner for Research Innovation and
Science, Maire Geoghegan-Quinn, in 2012 described RRI as
contributing to the Europe 2020 Strategy on the creation of‘a smarter, greener economy where our prosperity will come from
research and innovation … [and] research and innovation must
respond to the needs and ambitions of society, reflect its values
and be responsible’ [7]. The key areas of RRI are described as: (i)
engagement, (ii) gender equality, (iii) science education, (iv) open
access, (v) ethics and (vi) governance.
In this paper, we analyse the background and context for
development of RRI in the EU, current approaches to the conduct
of responsible research (RR) with its focus on upstream
engagement, and the need now to translate that to a workable
approach to responsible innovation (RI). It will propose new
approaches to taking forward legitimate public expectations for
responsible behaviour by companies and innovators in the
development of new technologies in a way that encourages
equitable representation of the views and interests of all relevant
stakeholders, and also provides a route to verifiable delivery of RI
in practice.2 RRI and its origins
2.1 The ELSA agenda and the emphasis on
upstream engagement
The antecedents of RRI lie in an earlier research initiative that
focused on ethical, legal and social aspects of new technologies
(ELSA), from 1994 in the 4th EU Framework Programme [8].
So-called upstream engagement, starting from engaging about
early decision making on basic research funding, was seen as the
best option to avoid future societal conflicts over life science
research and its applications [9]. Research funded under the ELSA
agenda and led by academics in the science and technology
studies discipline has played an important role both in framing
public responses to genetic modification and other innovative
technologies and in channelling public responses to these
technologies into government decision making on science funding
and the development of EU regulatory systems [10–13].1
Table 1 Problems with upstream stakeholder engagement (adapted
from [13])
Group think The views of small groups, e.g. focus groups, are
easily swayed by participants with strong opinions
or by those leading the engagement
Issue framing Given our ignorance about the future, upstream
engagement can be a process of fictitiously framing
new science and technology in the minds of the
public
Recruitment bias It is difficult to persuade uncommitted citizens to
participate in hypothetical discussions about future
science and innovation — recruitment is likely to be
biased towards those who have a specific agenda
Consensus and
conflict
Even in a small group discussion there is unlikely to
be agreement on any issue related to innovative
technologies, and where there is polarisation of
views, upstream engagement can lead to increased
levels of conflict and more extreme polarisation
Engagement focus Some topics, for example nanotechnology or
synthetic biology, are too broad and multifaceted to
allow meaningful engagement, particularly at the
upstream stage
Engagement
fatigue
There will be insufficient time and resources to
engage on every relevant issue and people will
become cynical about the process
Labile public
opinion
Most people who do not already have strong
opinions will change their minds over relatively
short timescales, and much more so over the 10–15
years that will elapse before a disruptively
innovative research initiative delivers tangible
outcomes in a market placeAn important event in enabling the policy influence of ELSA
research in the UK was the launching by the think tank Demos of
the booklet ‘see through science: why public engagement needs to
move upstream’ [14] the front cover of which made clear its
political ambitions – ‘the task is to make visible the invisible, to
expose to public scrutiny the assumptions, values and visions that
drive science’, and which on p24 suggested that its logical
conclusion was ‘… not only [to] change the relationship between
science and public decision making but also the very foundations
of knowledge on which science rests’ (our emphasis). In the
periods leading up to and beyond the launch of the Demos
booklet, social science research on innovation-related questions in
the UK and the EU was heavily dominated by this ELSA agenda.
Despite this overt challenge to the scientific ethos, scientists and
science funders embraced upstream engagement on the basis that it
would, if managed properly, improve public acceptance of new
technologies and would not bring an end to any area of research
[15]. However, although upstream engagement has been widely
undertaken, for example by UK research councils [16, 17], there is
not yet any evidence that better public acceptance of new
innovative technologies will result from such engagement [18] and
in practice there have been reductions in funding for some areas of
science, particularly in nanotechnology [19, 20] and plant
biotechnology, arising from political and policy concerns about
negative public opinion rather than evidence of potential or actual
harm arising from the innovations concerned. Such considerations
have also influenced the extent to which genetically modified
crops are being cultivated in Europe [21].
The further upstream the engagement, the more remote and
uncertain the future innovative products, process or services will
be from the needs and concerns of citizens, and in such
circumstances citizens are more likely to engage with an issue on
the basis of values or ideology rather than local or personal
interests [22, 23]. In such cases, conflict and polarisation of views
are more likely to arise and resolution of any conflict will be more
difficult to achieve [24]. In essence, the more developed a
particular novel application towards its end purpose, the more
deliberative and meaningful the conversation is likely to be. When
citizens are unfamiliar with the issues at stake, engagement —
whether upstream or downstream — can become a process of
framing these unfamiliar developments, either favourably or
unfavourably, in the public mind, potentially giving considerable
power to those who conduct the engagement [14]. Table 1 outlines
some of the potential problems with engagement at the ‘upstream’
stage of research on an innovative technology.2.2 RRI as part of European research and
innovation agendas
The shift from ELSA to RRI in EU funding initiatives has been
described by Zwart et al. as ‘a new initiative in the labelling
arena’, reflecting a shift in emphasis on the part of research
funders towards ‘collaboration with industry and potential
socioeconomic benefits of scientific and technological change’ [8].
Zwart et al. note in the conclusion of their paper that, although
RRI was presented as a new approach fostering closer links with
innovation processes, it has yet to be articulated by its proponents
in a way that clearly distinguishes it from ELSA, observing that
achieving the shift of emphasis desired by the funders will require
collaboration with a broader range of academic disciplines,
including management and innovation studies where researchers
have an understanding of how innovations come about, how they
are managed and how policy affects them.
Until recently RRI researchers have focused their attention almost
entirely on basic science and research and on upstream engagement
as means to deliver the responsible behaviour that citizens are
presumed to demand [14]. Initiatives in the Framework 7 research
programme, most receiving more than a million Euros, included
Governance for Responsible Innovation, Res-AGorA, ProGReSS,
Responsibility, Synenergene and Rising pan-European and
International Awareness of Biometrics and Security Ethics.2 This is an openThe Horizon 2020 research programme in 2015, including only
those calls with RRI in the title, had 21.8 M Euros of funding
available [25] and the latest call under the ‘Science with and for
Society’ heading has allocated over 42 M Euros for 14
RRI-related projects [26], with a much stronger focus on industry
taking a leadership role than previous funding rounds.2.3 The politicised nature of RRI initiatives
A recent RRI publication [27] comments on a group of scientists
(Drew Endy, Jay Keasling, Dick Kitney, Paul Freemont and
J. Craig Venter) as ‘high-profile techno-visionaries and political
actors … who have been most successful in securing funding
for synthetic biology, publishing in high-profile papers, gaining
international prestige and exerting considerable, even
disproportionate influence’. However, from the launch of the
Demos publication on upstream engagement [14] to the academic
discourse on RRI, this political bias in a different direction is
present but is rarely commented on – the lead commentators on
RRI could be described as high-profile ‘socio-visionaries’ and
political actors with similar attributes.
Kuntz [28] has criticised ‘… the worrying ideological shift
towards postmodernism which aims to deconstruct Enlightenment
values’ and describes the ‘democratisation of science’ as a socially
coercive tool for the political control of science [29], and an
exchange of correspondence in Nature [30–32] demonstrates the
contrast in positions of scientists and social scientists around such
issues. Contributing to a sense of distrust in the RI process by
innovating organisations and companies, the tone of some
recommended lines of questioning seems to presume that some
things that are publicly unacceptable would otherwise remain
hidden, and to suggest an open-ended process that may never
reach a conclusion: why are researchers doing it, are these
motivations transparent and in the public interest, what do not we
know about and what might we never know about? [27].
Politicisation from a range of different perspectives is not
uncommon in debates and analyses of issues related to science and
innovation, particularly where the innovation is potentially
disruptive, and the perception of politicisation can affect the
willingness of stakeholders to participate in an engagement
initiative, as was the case in early attempts by technology strategy
board (TSB) to engage industry actors in RRI processes in the
UK. However, reinforcing a political or ideological debate whichEng. Biol., pp. 1–5
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is only of interest to a minority of the population will be unhelpful in
moving forward with a workable approach to encouraging
responsibility in research and innovation. The interests of the
majority of citizens will probably be best served by an approach
that attempts to maintain an equitable balance across the broad
range of values and interests likely to be found in any
representative sample of citizens.3 Demonstrating responsible innovation –
a consolidated RI framework (CRIF)
To add to the political complexity noted above, most of the research
papers on RRI, including most of the contributions to the Journal
of Responsible Innovation, have been about RR and not RI. There
is a clear need now to move beyond the focus on the research
community and to consider the very different issues faced in more
downstream innovation processes, the different sets of actors and
stakeholders that will need to be involved and the need to make
decisions on timescales that reflect the real challenges faced by
companies in a competitive economic environment. A first attempt
to consider the specific needs of innovators was the development
in 2012 of a responsible innovation framework (RIF) by the TSB
(now innovate UK) [33]. The CRIF described in this paper builds
on experience of involvement with implementation of the TSB
RIF and attempts to simplify it and develop it further for use by
synthetic biology/engineering biology companies. The proposed
consolidated framework also incorporates guidance produced by
UK research councils led by the Engineering and Physical
Sciences Research Council (EPSRC) [34], the anticipate, reflect,
engage and act (AREA) approach which, although addressing
mainly the behaviour of researchers, can also be adopted to guide
the behaviour of innovators at later stages in the development of
products, processes or services.
The TSB RIF aimed ‘… to fund projects where the ‘anticipated
commercial use’ of the project outcomes meets, on the balance of
positive and negative drivers, the standards outlined ‘… for
responsible innovation’, and ‘… to help companies anticipate and
give responsible consideration to the intended and potential
unintended impacts of the commercial development and use of the
technology, including the potential for misuse, before the work
begins’ (TSB emphases) [33]. It was directed to the activities of
companies at all stages in the innovation process, from new
spin-out companies to multinational corporations. In developing
the RIF, the TSB was faced with the general lack of understanding
on how the concept of ‘responsibility’ could best be applied in
the context of innovation and built heavily on the standards
for corporate social responsibility adopted by large companies,
particularly in the financial sector.Table 2 Routine, company-specific RI elements related to standard business p
Positive and
negative drivers
1. Promoting sound practices in employment,
business behaviour and ethics
Organisati
including r
child or co
2. Absence of clear policies and procedures on
bribery and corruption
Organisati
employees
3. Inappropriate use of human or animal
products and substitutes
Partners sh
4. Testing products on animals Testing on
office guid
5. Business in countries that violate the political
and civil rights of their people
Where the
in these re
human rig
6. Production or sale of weapons Deriving re
non-defen
7. Addictive substances and behaviours Projects le
8. Familiarity and compliance with existing
regulations relevant to the project
Organisati
funding; o
relevant re
Eng. Biol., pp. 1–5
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(factors in favour of supporting projects), (ii) negative drivers
(factors against supporting projects) and (iii) regulatory drivers, as
described in more detail below. Applicants for funding were
required to demonstrate that they met these requirements. The
consolidated framework proposed here is based on these two UK
initiatives: EPSRC AREA approach and TSB RIF. It is seen as
potentially more appropriate to the innovation context than most
RRI initiatives so far proposed. The starting point for developing
the consolidated framework was to separate the requirements
specified in the TSB RIF into routine aspects and project-specific
aspects as described below.3.1 Routine aspects of RI compliance
The TSB RIF drivers in Table 2 can be seen as routine in nature,
specific to the company or organisation developing the innovation,
to be dealt with as part of the pre-award project evaluation
process. They include one ‘positive driver’ and seven ‘negative
drivers’ and it is clear that the distinction in this list and in Table 3
between positive and negative drivers is a semantic one – any
driver could be worded positively (‘organisations that promote
sound practices’ will be eligible for funding) or negatively
(‘organisations that do not have clear policies on bribery and
corruption’ will not be eligible for funding).
Organisations applying for funding would be expected to have
policies already in place to deal with these ‘routine’ drivers and
any deficiency would lead to rejection of a proposal or at least
postponement of funding until the issue is addressed. Once a
project is approved for funding ongoing monitoring would be a
matter of routine surveillance through the organisation’s standard
operating procedures and the EPSRC AREA requirements will not
be relevant to these ‘routine’ aspects of implementation of RI.3.2 Project-specific aspects of RI compliance
The project-specific elements of RI from the TSB RIF, included in
Table 3, relate to properties of the innovation itself rather than
attributes of the company or organisation and they will vary across
projects, including different projects conducted by the same
organisation. They may require action during the conduct of a
project, should be considered on an ongoing basis and are likely to
require more than routine monitoring as the project progresses,
potentially also requiring adaptation of the original plans.
The elements of the AREA Framework (7–10 in Table 3) are
different in character from those that are incorporated in the TSB
RIF (1–6 in Table 3). They describe actions to be undertaken by
an organisation to deliver the requirements outlined in elements
1–6 and their role is elaborated below in the context of Table 4.ractice
Criteria
ons should encourage principles of good business behaviour and ethics,
esponsible sourcing, fairness, human rights, privacy, the avoidance of
erced labour, and accountable governance
ons should have appropriate policies in place, including guidance for
ould commit to adopting the appropriate codes and regulations
animals should be kept to a minimum and should comply with home
elines
market or components of the supply chain involve countries rated poorly
spects, the organisations concerned should have effective policies on
hts
venues from this source outwith international treaties and/or for
ce purposes is discouraged
ading to these outcomes are discouraged
ons convicted of an offence within the last 3 years are not eligible for
rganisations should demonstrate that they are familiar, and comply, with
gulations
3Commons
Table 3 Project-specific elements of RI requiring active consideration
and monitoring as a project evolves
Source Element
TSB RIF positive drivers (factors
in favour of supporting projects)
1. Products and services that benefit
society and/or human well-being
2. Making a positive contribution to
the environment
3. Promoting sound practices in
employment, business behaviour and
ethics
TSB RIF negative drivers
(factors against supporting
projects)
4. End uses leading to social damage
5. End uses leading to environmental
damage or pollution
TSB RIF regulatory driver 6. Regular reassessment of regulatory
requirements and implementation of
any necessary regulatory changes
EPSRC AREA elements 7. Anticipate – describing/analysing
potential impacts relevant to the
project
8. Reflect – on purposes of,
motivations for and potential
implications of the project and
associated uncertainties
9. Engage – opening up visions,
impacts and questioning to broader
deliberation and dialogue
10. Act – using the above processes to
influence the direction and trajectory
of the research and innovation
process.The semantic distinction between positive and negative drivers is
also evident in elements 1–6. Given research showing that, from
the perspectives of both regulators and the organisations being
regulated, incentives work better than disincentives [35] (compare
elements 4 and 1 and elements 5 and 2 in Table 3), we have
reworded these issues as positive elements in our consolidated
RI framework. This could help to facilitate compliance with
RI-related expectations of companies and organisations and
reinforce positive public expectations of organisational behaviour.
For these reasons, in developing this consolidated framework for
RI, negative drivers have been reworded to indicate a positive
inducement for organisations to behave in the expected manner.
This approach also allows simplification and consolidation of
RI-related requirements.3.3 Proposed CRIF
The CRIF brings together the elements of the TSB RIF and the
Research Councils’ AREA approach, as an interim measure to
enable delivery of RI from a perspective that takes account of the
needs of innovators as well as meeting societal expectations. It can
be seen as a baseline on which new initiatives could usefully
build. It focuses on a project-specific set of societal, environmental
and regulatory elements, using the AREA elements to guide the RI
compliance process. It assumes that routine drivers of an RIF
(Section 3.1) will be addressed as part of a company’s standard
operating procedures and focuses on the project-specific elements
(Section 3.2) that will be monitored regularly throughout the
development of a new product, process or service, given theTable 4 Consolidated RI framework
Elements of RI Issues arising during the project
societal element
environmental element
business practice element
regulatory element
4 This is an openchanges likely to emerge over time in the nature of the innovation
itself, its expected market and the applicable regulatory systems.
The consolidated framework aggregates the drivers of the TSB
RIF into societal, environmental, business and regulatory elements
(Table 4).
The societal element incorporates elements 1 and 4 of Table 3 as
a single positive requirement, adapting the language in the TSB RIF
document to remove ambiguities and to focus on the kinds of issues
likely to be relevant to an innovating organisation, rephrasing the
negative language of element 4. Some initiatives will include both
societal and environmental elements but any single project will not
necessarily include both.
Where appropriate, the organisation will: develop products,
processes or services designed to deliver societal benefits that
are life-saving and life-enhancing or contribute to other
societal needs, including education, arts, housing, and
employment; minimising risks and supporting equitable
distribution of risks and societal and economic benefits;
protecting human dignity; and avoiding misuse or deliberate
harm.
The environmental element similarly incorporates elements 2 and 5
of Table 3.
Where appropriate, the organisation will develop products,
processes or services that enhance and support the
environment, for example through green transport, waste
minimisation, improved efficiency of water use and resilience
of water systems, conservation of non-renewable resources,
increased use of renewable resources, and considering
lifecycle impacts including second and third order effects;
ensuring that end uses or processes lead to a net reduction in
environmental damage or pollution.
Some aspects of element 3 in Table 3 are captured as routine
elements in Table 2: Item 1 (encouraging principles of good
business behaviour and ethics; having clear evidence of excellent
health and safety systems and a good track record of health and
safety issues). The business practice element in Table 3 relates to
issues that will require more active project-specific surveillance,
for example where new organisations and/or collaborators become
involved during development of a product, process or service.
Good business practices should be observed by the organisation
and any associates involved in a project in responsible
sourcing, fairness, human rights, privacy, the avoidance of
child or coerced labour and accountable governance.
The regulatory element (element 6 in Table 3) goes beyond
compliance with existing regulations that would be captured as a
routine element. In areas such as synthetic biology/engineering
biology, where regulatory systems are in a state of flux, there is a
need to monitor actively the regulatory environment to ensure
awareness of changes that may affect an organisation’s future
activities.
Organisations should commit to regular reassessment of
regulatory requirements as the project develops and to
implementing any relevant regulatory changes.
Table 4 outlines the proposed consolidated RI framework,
incorporating the AREA elements to guide and capture responses
to the four CRIF elements: it is the responsibility of theOrganisation responses
Anticipate Reflect Engage Act
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organisation to anticipate emerging potential issues throughout
conduct of the project. On reflection, some will require
engagement and/or action, but others will not, so it is not
appropriate to expect every box in this matrix to be addressed to
demonstrate responsibility. The CRIF is an attempt to clarify and
simplify the process of compliance with RI requirements in the
context of innovative biotechnologies such as synthetic biology/
engineering biology. It will be relevant to both small and large
companies and research institutes as they move from basic
research in these areas to the development of products, processes
and services.4 Conclusions and future developments in
RI compliance by companies and organisations
There has been little coordination across organisations tasked
with implementing an RI approach, and no consensus around
what should constitute such an approach. As currently being
implemented, ‘responsible behaviour’ requires scientists and
innovators to undertake effective public engagement about planned
research and future innovative developments and then to adapt
them where necessary to comply with the development of ‘…
harmonious models for responsible research and innovation that
integrate public engagement, gender equality, science education,
open access and ethics’ [7]. The absence of any reference to
innovation or the societal benefits it may be able to deliver are
notable, as is the assumption that there will be a societal
consensus on which to base such policies.
What is lacking is a means to move beyond current RR initiatives
and develop an approach to RI that transcends current academic
disciplinary structures and is based on an understanding of
innovation processes and strategies in different technology sectors.
Success in this initiative will depend on demonstrating that any
suggested approach will not incorporate covert politicisation in any
direction, as discussed in Section 2.3. The CRIF (Section 3.3)
proposes a basic framework that (i) could be adapted for future
innovative developments in a broad spectrum of innovative
technologies, (ii) could satisfy a broad spectrum of societal needs
and desires and (iii) does not unnecessarily delay or inhibit
commercialisation of products, processes or services.
In future RI-related initiatives, the relevant industry sectors will
have an important proactive role to play in their development, but
this process has not yet begun in any formal sense. It is also
notable that, throughout all discussions and recommendations on
RR and RI, the focus has been entirely on the need for scientists
and innovators to behave responsibly. Based on the ethical
principle of equitable treatment of all stakeholders, the field is
open for new approaches to RR and RI that also include the
desirability of responsible behaviour by stakeholders and citizens
(in engaging ‘responsibly’ with other stakeholders) [13], as
currently being considered in a project funded by the British
Standards Institution [36].5 References
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